Just google it to see more..., sorry if it is old news....
"In California, hyrogen fuel stations are in the early stages of a massive infrastructure buildout.
Yet, fuel cell cars have some advantages over battery electric cars. Batteries are extremely expensive to manufacture, the recharging times are long, and many people have nowhere to charge batteries overnight or at work during the day.
Specifically in California, Hyundai (HYMTF) is already in the hydrogen fuel cell car market, and Honda (HMC) and Toyota have committed to rollout plans beginning next year. Other automakers have test fleets in operation and are widely believed to be launching commercially at various points between 2016 and 2025."
Solar power used to be very expensive but Chinese makers lowered its cost and it can compete with coal power now. We need Chinese maker to make FC car/stack in order to make it affordable for main street people.
When Toyota commercialized the gas-electric hybrid cars few years ago, most other car makers did not think it could get popular and not affordable. As a result, Toyota sold a lot of hybrid cars before other car makers rushed to catch up. Now it is the same for fuel cell car, these same car makers are just watching while Toyota is going to sell FC cars next year. I have high hope on Toyota FC cell, it just needs a little government support.
How often you see any of these ANAlysts get rich and quit their job for early retirement ? There ANALysts just keep talking and don't know investing at all...
stem cells can do a lot of things, it can basically rebuild any of your organ, but you need to use your own cells, otherwise your body keeps rejecting foreign cells. and many people still against using unborn baby cells.
MannKind ($MNKD) has been starved for cash, so it was huge for the California-based pharma to strike a deal with Big Pharma player Sanofi ($SNY) to help market its inhaled insulin Afrezza. But Sanofi has something else that can cut the pair's costs and fatten up its bottom line. It has insulin.
Of course, the company with the best-selling diabetes product in the world, Lantus, would have insulin. Now, if the partners can get a Sanofi insulin approved for the Afrezza product, then MannKind will get it at cost and that can make Afrezza more competitive, Mannkind CFO Matthew Pfeffer told investors at the Morgan Stanley Global Healthcare Conference last week. That will fatten their margins on Afrezza.
"They can certainly make it more cheaply than we can buy it anywhere else, which only helps both of us since this comes off the bottom-line, which we then split," Pfeffer said, according to a transcript of the discussion from Seeking Alpha. That just adds to the "attractiveness of doing a deal with somebody like Sanofi."
buy low !
PP&A has a big market, why don't they order more ? Only 13 !? They have tested it for 2 years, it is already proofed.
Not sure how long you mean. Anyway, I made few more dollar today. Thanks.